1,024 material Form 8-K filings that 799 companies we cover made with the SEC in August 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On August 8, 2025, Amphastar entered into an exclusive license agreement with Nanjing Anji Biotechnology for three peptide-based products in the United States and Canada, and announced it on August 12, 2025. Amphastar paid $0.75 million in earnest money and a $5.25 million upfront payment, with further development and sales milestone payments of up to $42 million and $225 million, contingent on achieving those milestones. The filing ties the deal to Amphastar's pipeline expansion, but the payments depend on future milestones and commercial results.
Agreement signed August 8, 2025; covers three identified peptide products in the US and Canada.
Upfront costs: $0.75 million earnest money and $5.25 million upfront payment to Anji.
Potential payments: up to $42 million in development milestones and up to $225 million in sales milestones.
Royalties owed by Amphastar are capped at $22.5 million per calendar year and $60 million accumulated per product.
Daxor Corporation announced FDA 510(k) clearance (K251087) for its next-generation, rapid, portable lab-based Blood Volume Analyzer (BVA), according to a press release dated August 7, 2025. The filing does not include financial results or a financial impact estimate, so its effect on shareholders is not quantified.
FDA 510(k) clearance was granted under number K251087 for the new Daxor BVA device.
The company says the device provides results three times faster than its predecessor and weighs 7 lbs.
The system was developed under contract with the U.S. Department of Defense, including the U.S. Army and the Defense Health Agency.
The company states that more than 75,000 tests have shipped to date.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.